Key result
SwedeHF registry enrollment is linked to an ~8% lower risk of major CV events.
Why the study?
Does enrollment in a heart failure quality registry improve adherence to guideline-directed medical therapy and clinical outcomes in patients with incident heart failure?
Observational (n=48,374)
Does enrollment in a heart failure quality registry improve adherence to guideline-directed medical therapy and clinical outcomes in patients with incident heart failure?
Answers are grounded in this paper and cite their sources.
Enrollment in a heart failure quality registry is associated with better adherence to guideline-recommended therapies and improved clinical outcomes, though registry patients represent a younger, healthier minority of the overall heart failure population.
INTRODUCTION: Quality registries may involve specific inclusion criteria, detailed investigations, or selected hospitals and practitioners, which are not random. Whether the care and outcomes in quality registries are generalizable to the broader population is not well known. We here examine care indicators and outcomes in heart failure (HF) patients enrolled vs. non-enrolled in Swedish Heart Failure (SwedeHF) quality registry. METHODS AND RESULTS: Observational study of 90-day survivors after a HF in Stockholm (2012-2021). We linked health records from the Stockholm Creatinine Measurements project with SwedeHF. Participants enrolled in SwedeHF were compared to those non-enrolled, focusing on settings of care, use of guideline-recommended therapies, treatment adherence, dose titration, persistence, and outcomes. Analyses considered stratification by settings of management (primary care, cardiology-outpatient, and cardiology-inpatient care). We identified 48 374 incident HF cases of which 4878 (10%) were enrolled in SwedeHF within 90 days. Enrolled participants were younger, more often men and had fewer comorbidities than non-enrolled. Enrolled participants were more likely to initiate, persist and adhere to, and achieve higher dosages of guideline-recommended HF therapies (P < 0.05 for all). Enrolled participants were less likely to experience a major cardiovascular event [CV death, nonfatal myocardial infarction or stroke; HR 0.92, 95% confidence interval (CI) 0.86-0.99] and all-cause death (HR 0.87, 95% CI 0.82-0.92), but had similar rates of HF hospitalization (HR 1.03, 95% CI 0.94-1.15) compared to non-enrolled ones. Findings were similar across settings of management. CONCLUSION: Enrollment in the SwedeHF registry occurred in a minority of patients, and was associated with better adherence to guideline-recommended HF therapies and fewer major cardiovascular events and lower mortality. The generalizability of these HF registry findings to all HF patients was, however, limited.
No takes yet. Share an insight, caveat, or question.
González-Ortíz et al. (2025) conducted an observational in Heart failure (n=48,374). Enrollment in the Swedish Heart Failure (SwedeHF) quality registry vs. Non-enrolled patients was evaluated on Major cardiovascular event (CV death, nonfatal myocardial infarction or stroke) (HR 0.92, 95% CI 0.86-0.99). Enrollment in the SwedeHF registry was associated with a lower risk of major cardiovascular events and all-cause death compared to non-enrolled heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: